SSStuart Schwartz

Stuart Schwartz

*This is an algorithmically generated author record based on publicly available information.

Stuart Schwartz has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cytogenetic and Microarray Analysis Follow‐Up of PGT‐A Mosaic and Sex Discrepant Embryos During Pregnancy: Absence of Confirmation and Follow‐Up Recommendations

    by Laura A. Kline, Vanessa A. Nitibhon, Brittany Dyr, Erica L. Soster, Amanda Sussman, Vivian J. Weinblatt, Stuart Schwartz

    Objectives: The objective of this study was to examine the concordance of results between mosaic pre‐implantation genetic testing for aneuploidy (PGT‐A) and diagnostic testing in resulting pregnancies conceived by IVF with PGT‐A. Methods: This study retrospectively provides analysis of 328 patients ascertained due to a mosaic PGT‐A finding and 25 with a discordant reported sex, studied prenatally, utilizing standard karyotype and/or SNP microarray analysis. Results: None of the 328 mosaic PGT‐A findings were confirmed by the diagnostic prenatal studies with karyotype and/or microarray analysis. Additionally, of the 298 prenatal microarray studies performed, five demonstrated pathogenic abnormalities (1.7%) that were unrelated to PGT‐A referral. Thirty‐four of these cases were also studied to determine if UPD occurred; all were biparental. Conclusions: This work emphasizes the importance of PGT‐A follow‐up and demonstrates that the vast majority will have normal diagnostic results and only a small number will be confirmed using prenatal diagnostic analysis. This work also suggests the most efficient way to proceed with diagnostic follow‐up studies. Additionally, it shows the importance of fetal sex confirmation in all normal PGT‐A studies.


  • Open Access

    Prenatal Microarray Analysis of Pregnancies Without Ultrasound Anomalies: Establishment of Copy Number and Homozygosity Frequencies in Low-Risk Population

    by Stuart Schwartz, Robert G. Best

    Objectives: The overall objective of this study is to examine prenatal patients ascertained without an abnormal ultrasound (US) or an abnormal cell-free DNA (cfDNA) finding to provide a unique understanding of pathogenic copy number variants, identity by descent (IBD) and variants of uncertain significance (VUSs) in a normal population. Methods: This study retrospectively provides an analysis of over 28,362 prenatal specimens ascertained without an abnormal US or abnormal cfDNA finding utilizing an SNP microarray. These specimens include at least 10 different ascertainment groups, including advanced maternal age (AMA), anxiety, abnormal maternal serum screen (MSS) with/without AMA, and a previous or familial child/pregnancy with a chromosome abnormality or a genetic disorder. Results: This study provides a basic understanding of pathogenic copy number variants (CNVs), homozygosity and VUSs in an essentially normal population. This low-risk population has a frequency of pathogenic CNVs of ~1.26%; however, ~52% were associated with neurodevelopmental microdeletions/microduplications and ~13% were associated with incidental findings. Overall, ~1.32% of these patients showed an increase in homozygosity, the majority due to consanguinity. Lastly, VUSs were seen in 1.41% of this group, of which ~90% were familial. Conclusions: Overall, these findings provide a better estimate of the baseline frequencies and types of pathogenic CNVs and homozygosity in a low-risk population. It provides insight into the distribution of stretches of homozygosity associated with identity by descent in this population and gives a better understanding of the extent of variants of uncertain significance in phenotypically unaffected individuals.


  • Detection of Isodisomy Utilizing SNP Microarray: Frequency, Ascertainment, and Implications

    by Sharon Molinari, Niecy Williams, Gloria Haskell, Andrea Penton, Alexandra Arreola, Inder Gadi, Karen Phillips, Jim Tepperberg, Stuart Schwartz

    This study investigates the frequency, ascertainment, and clinical implications of whole chromosomal isodisomy using a database of over 415,000 chromosomal microarray (CMA) tests conducted since 2008 across prenatal, postnatal, and products of conception specimens. In this cohort, 0.04% of cases exhibited the rare chromosomal phenomenon of isodisomy. Analysis of these cases revealed distinct patterns in frequency, chromosome involvement, and parent of origin related to specimen type. Isodisomy 14 was most frequent in prenatal samples, while chromosomes 6, 7, and 15 were more common in postnatal cases. The involvement of imprinted and non‐imprinted chromosomes was equivalent for prenatal cases, while imprinted chromosomes consisted of two‐thirds of postnatal cases, with paternal uniparental isodisomy more prevalent than maternal across all specimen types. Several cases demonstrated unmasking of pathogenic variants in recessive genes, and findings support prior studies of associations between isodisomy 11 and prenatal or neonatal lethality. These results underscore the diagnostic value of CMA and contribute to an extended understanding of isodisomy's clinical relevance.

  • Mosaicism for Genome Wide Homozygosity Identified as an Incidental Finding in Two Apparently Healthy Pregnant Women

    by Gloria T. Haskell, S. Hussain Askree, Laura Kline, Linda Hasadsri, Huong Cabral, Inder Gadi, Stuart Schwartz

    Uniparental Disomy (UPD) occurs when both copies of a chromosome or chromosomal segment originate from only one parent. Mosaic genome‐wide UPD (mos gwUPD) is typically identified in cases of fetal demise and placental dysplasia or in prenatal cases, where imprinting effects are associated with abnormal ultrasound findings. Children with mos gwUPD and clinical features due to UPD‐associated imprinting effects (especially Beckwith‐Wiedemann syndrome) have been reported; however, reports of adults with mos gwUPD are rare. Here we describe mos gwUPD in two apparently healthy pregnant adult women. Carrier testing noted variants with skewed allelic ratios outside of the normal heterozygous range, prompting further testing. Single nucleotide polymorphism (SNP) microarray identified mosaicism for gwUPD in both individuals, present at 85% and 90%, respectively, in blood, with varying percentages in other tissues. Neither woman displayed clinical features that would be expected with gwUPD at the time of testing, although retrospective careful personal history was consistent. Both women had uneventful pregnancies and delivered full‐term healthy infants. These two cases demonstrate that mos gwUPD can be an incidental finding identified in apparently healthy adult women. Clinical follow‐up is important for tumor monitoring, genetic counseling, and monitoring of future pregnancies due to mos gwUPD in the maternal endometrial tissue.

  • Utilization of a SNP microarray to detect uniparental disomy: Implications and outcomes

    by Alexandra Arreola, Gloria Haskell, Inder Gadi, Andrea Penton, Stuart Schwartz


  • Prenatal detection of mosaicism for a genome wide uniparental disomy cell line in a cohort of patients: Implications and outcomes

    by Margriet Johansen, Gloria T. Haskell, Alexandra Arreola, Christine Riordan, Inder K. Gadi, Andrea Penton, Peter R. Papenhausen, Stuart Schwartz

    Objectives: To investigate the prenatal detection rate of mosaicism by SNP microarray analysis, in which an individual has not one, but two, complete genomes (sets of DNA) in their body, a normal biparental line with a Genome Wide Uniparental Disomy (GWUPD) cell line was used.Methods: This study retrospectively examines the prenatal detection of GWUPD in a cohort of ∼90,000 prenatal specimens and ∼20,000 products of conceptions (POCs) that were studied by SNP microarray.Results: In total, 25 cases of GWUPD were detected; 16 cases were detected prenatally with GWUPD (∼0.018%) and 9 POCs revealed GWUPD (0.045%). The nine POC specimens presented with placental abnormalities. The 12 amniotic fluid specimens were ascertained because of abnormal ultrasound findings. Nine of 12 pregnancies had findings consistent with Beckwith‐Wiedemann syndrome or because of abnormal placentas. However, three pregnancies were detected with GWUPD of maternal origin, with less common findings and demonstrated maternal origin. Four other pregnancies showed GWUPD in a chorionic villus sample, but normal findings in amniotic fluid and apparently normal fetal development.Conclusions: This cohort with GWUPD mosaicism expands our understanding of GWUPD and has implications for prenatal care and counseling. Additional studies are necessary to understand the rarer maternal GWUPD.


  • Multidisciplinary analysis of pediatric T-ALL: 9q34 gene fusions

    by Peter Papenhausen, Carla A. Kelly, Zhenxi Zhang, James Tepperberg, Rachel D. Burnside, Stuart Schwartz


  • Yield of additional genetic testing after chromosomal microarray for diagnosis of neurodevelopmental disability and congenital anomalies: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

    by Darrel Waggoner, Karen E. Wain, Adrian M. Dubuc, Laura Conlin, Scott E. Hickey, Allen N. Lamb, Christa Lese Martin, Cynthia C. Morton, Kristen Rasmussen, Jane L. Schuette, et al.


  • Clinical experience of laboratory follow‐up with noninvasive prenatal testing using cell‐free DNA and positive microdeletion results in 349 cases

    by S. Schwartz, M. Kohan, R. Pasion, P. R. Papenhausen, L. D. Platt

    Objective: Screening via noninvasive prenatal testing (NIPT) involving the analysis of cell‐free DNA (cfDNA) from plasma has become readily available to screen for chromosomal and DNA aberrations through maternal blood. This report reviews a laboratory's experience with follow‐up of positive NIPT screens for microdeletions.Methods: Patients that were screened positive by NIPT for a microdeletion involving 1p, 4p, 5p, 15q, or 22q who underwent diagnostic studies by either chorionic villus sampling or amniocentesis were evaluated.Results: The overall positive predictive value for 349 patients was 9.2%. When a microdeletion was confirmed, 39.3% of the cases had additional abnormal microarray findings. Unrelated abnormal microarray findings were detected in 11.8% of the patients in whom the screen positive microdeletion was not confirmed. Stretches of homozygosity in the microdeletion were frequently associated with a false positive cfDNA microdeletion result.Conclusions: Overall, this report reveals that while cfDNA analysis will screen for microdeletions, the positive predictive value is low; in our series it is 9.2%. Therefore, the patient should be counseled accordingly. Confirmatory diagnostic microarray studies are imperative because of the high percentage of false positives and the frequent additional abnormalities not delineated by cfDNA analysis.